Hospital Price Transparency Rule<\/a><\/strong>, a requirement for hospitals to publicly disclose detailed \u201cstandard charges\u201d in prescription drug prices. However, the report\u2019s analysis found this has done little to address vastly different prices across the country.<\/p>\n\u201cWhile there is often consistency in list prices presented to payers and patients, the majority of a hospital\u2019s patients \u2013 those with insurance \u2013 face a confusing array of potential prices,\u201d the report reads.<\/p>\n
The report also found other popular prescription drugs including Ocrevus, to treat multiple sclerosis, ranged from $16,000 to $65,000; Tysabri ranged from $6,500 to $27,000.<\/p>\n
\u201cThese pricing disparities are significantly large enough to theoretically fund travel expenses between the hospitals while still resulting in significant savings,\u201d the report reads.<\/p>\n
Indeed, the report estimated a patient could obtain Keytruda through United Healthcare in Colorado for $12,059, but would likely pay $43,099 in Massachusetts. Similarly, the cost for Darzalez Faspro, a treatment for myeloma, cost $9,311 in North Carolina compared to $36,300 in Wisconsin.<\/p>\n
Additionally, Tysarbi, a medication for multiple sclerosis and Crohn\u2019s disease, cost $6,477 through Cigna in Tennessee and $26,451 in New Jersey.<\/p>\n
\u201cWhile transparency requirements have unveiled price variations, they have yet to achieve meaningful price standardization, consumer usability, or systemic affordability,\u201d the report reads.<\/p>\n
The report called for greater transparency and structural reforms to insurance and hospital pricing metrics. It called for standardized billing based on the number of units sold in a drug.<\/p>\n
The report also called for hospitals to provide consumer-friendly search functions to negotiate and compare drug prices. Additionally, the report called on the Centers for Medicare and Medicaid Services to implement greater enforcement and oversight of its protocols.<\/p>\n
\u201cHospital data revealed a new level of dysfunction that surprised even us drug pricing cynics,\u201d said Antonio Ciaccia, president of 3 Axis Advisors. \u201cWhat we found wasn\u2019t just complexity \u2014 it was systemic chaos that makes it nearly impossible for payers and patients to understand or predict what they\u2019ll pay at the hospital.”<\/p>\n
The report comes as the Trump administration has sought to increase price transparency and lower insurance costs for millions across the country. Trump launched TrumpRx, a prescription drug tool for Americans to find prices on different products across the country.<\/p>\n
He has also sought to reduce prices for common prescription drugs to similar levels as European countries. Most-favored-nation pricing means the U.S. would pay no more than the lowest price paid by peer countries. Trump has thus far managed to get 17 of the largest drug manufacturers across the country to agree on most-favored-nations prices.<\/p>\n
\u201cThis represents the greatest victory for patient affordability in the history of American health care, by far, and every single American will benefit,\u201d Trump said.<\/p>\n
Advocates for reform have celebrated the administration\u2019s moves to reduce prices but have called for greater price transparency within the country as well.<\/p>\n
\u201cMaximum price transparency with stronger standardization and enforcement will allow patients to shop, make informed choices, and be protected from overcharges,\u201d said Cynthia Fisher, founder of Patient Rights Advocate.<\/p>\n","protected":false},"excerpt":{"rendered":"(The Center Square) – The price for the same prescription drug in different hospitals nationwide could have more…\n","protected":false},"author":2,"featured_media":381541,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[274],"tags":[6472,7544,18,135,474,19,17,20513,462,18270,175178,10942],"class_list":["post-381540","post","type-post","status-publish","format-standard","has-post-thumbnail","category-medication","tag-accountability","tag-colorado","tag-eire","tag-health","tag-healthcare","tag-ie","tag-ireland","tag-massachusetts","tag-medication","tag-national","tag-north_carolina","tag-wisconsin"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ie\/116216935917130745","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/381540","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/comments?post=381540"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/posts\/381540\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media\/381541"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/media?parent=381540"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/categories?post=381540"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ie\/wp-json\/wp\/v2\/tags?post=381540"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}